(Q35015856)

5 August 2017

1 reference

title

Cytokines: interleukin and interferon therapy in dermatology (English)

1 reference

5 August 2017

Asadullah K

1

1 reference

5 August 2017

Sterry W

series ordinal

2

1 reference

5 August 2017

Trefzer U

series ordinal

3

1 reference

5 August 2017

publication date

1 October 2002

1 reference

Clinical and Experimental Dermatology

5 August 2017

published in

1 reference

5 August 2017

volume

27

1 reference

5 August 2017

issue

7

1 reference

5 August 2017

page(s)

578-584

1 reference

Evidence for an epidermal cytokine network

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Cytokine therapy in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Systemic therapy of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Novel immunotherapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

Treatment of psoriasis with interleukin-10

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01144.X

10.1046/J.1365-2230.2002.01144.X

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference